UNSPSC 51311806: Mizolastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C24H25FN6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 244O1F90NA, chemically known as 4(1h)-pyrimidinone, 2-((1-(1-((4-fluorophenyl)methyl)-1h-benzimidazol-2-yl)-4-piperidinyl)methylamino)- but generally known as mizolastine, which bears US NIH Compound Identifier 65906. European Medicines Agency schedules Mizolastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09018MIG.

UNSPSC 51311806 Mizolastine is a Commodity code that nominally designates a specific antihistamine pharmaceutical, but recent state and local procurement activity shows little direct solicitation for mizolastine itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs that fall outside the scope of a single active pharmaceutical ingredient. State and local governments are using codes in this family to procure pharmaceutical supply agreements, wholesale distribution contracts, and emergency medical countermeasures through cooperative purchasing vehicles and direct buys. The issuing bodies include state health and human services agencies, county public health departments, and multistate cooperative purchasing alliances (notably the Minnesota Multistate Cooperative Purchasing Alliance administering contracts that span multiple states). These entities are seeking manufacturers and distributors capable of managing complex supply chains, meeting FDA compliance and Drug Supply Chain Security Act certification, maintaining relationships with authorized wholesalers, and delivering products on fixed timelines.

Recent activity shows geographic concentration in the Upper Midwest and Southeast. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating states including Oregon and Minnesota; evaluation weighs price competitiveness at 75 percent, with contract terms of two years plus optional extensions effective July 1, 2026. Seminole County, Florida issued an IFB (IFB60459723LAS, posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries and a two-year term plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026, response due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional pharmacy benefit manager and group purchasing organization arrangements. The code shows limited direct mizolastine-specific procurement; vendors should assess whether pharmaceutical supply chain, distribution, or generic multi-source contracting under multistate cooperatives aligns with their business model.